SCHEMBL683633

SCHEMBL683633

Cn1c(=O)c2c(ncn2CCN2CCC(C(=O)c3cccs3)CC2)n(C)c1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.51
HTR1A P08908 1/20 0.51
CHRM1 P11229 1/20 0.51
DRD2 P14416 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
ADORA2B P29275 8/20 0.47
LMNA P02545 1/20 0.47
HTR7 P34969 1/20 0.47
HTR6 P50406 1/20 0.47
ALDH1A1 P00352 3/20 0.46
RXFP1 Q9HBX9 3/20 0.45
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683617 0.82 CHRM2 (0.51) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL11386213 0.81 DRD2 (0.55) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL683632 0.81 CHRM2 (0.51) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL682797 0.81 ALDH1A1 (0.60) CHRM2HTR1ACHRM1DRD2ADRA1D
Flufylline SCHEMBL684324 0.81 HTR2A (0.60) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL684332 0.81 MAPK1 (0.55) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL684325 0.79 CHRM2 (0.49) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL683570 0.78 ADORA2B (0.48) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL683964 0.77 ADORA2B (0.47) CHRM2HTR1ACHRM1DRD2ADRA1D
SCHEMBL7316541 0.76 ALDH1A1 (0.59) CHRM2HTR1ACHRM1DRD2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF CHRM2 671/4885HTR1A 1265/4885CHRM1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.